AVALO THERAPEUTICS, INC. Debt Securities Available For Sale Excluding Accrued Interest
AVALO THERAPEUTICS, INC. (AVTX) had Debt Securities Available For Sale Excluding Accrued Interest of $91.55 million as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Balance Sheet › Assets
us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest · last filed 2026-03-23
- 2025-12-31: Debt Securities Available For Sale Excluding Accrued Interest $91.55M.
- 2025-09-30: Debt Securities Available For Sale Excluding Accrued Interest $104.69M.
- 2025-06-30: Debt Securities Available For Sale Excluding Accrued Interest $106.78M.
- 2024-12-31: Debt Securities Available For Sale Excluding Accrued Interest $0.00.
| Period end | Debt Securities Available For Sale Excluding Accrued Interest |
|---|---|
| 2025-12-31 | $91.55M 10-K · filed 2026-03-23 |
| 2025-09-30 | $104.69M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $106.78M 10-Q · filed 2025-08-07 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |